{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11"],"submitter":["McLaughlin VV"],"funding":["Johnson and Johnson"],"pubmed_abstract":["<h4>Introduction</h4>Upfront combination therapy with endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE5i) is guideline-recommended for low- or intermediate-risk pulmonary arterial hypertension (PAH). This study compared time to all-cause mortality for macitentan+PDE5i combination and each monotherapy.<h4>Methods</h4>Long-term patient-level data (planned follow-up ≥1 year) were pooled from four clinical trials and three observational registries. All-cause mortality data were available from adults with incident PAH initiated on macitentan 10 mg or PDE5i monotherapy, or macitentan+PDE5i. Propensity-score (PS) methods balanced key demographic and disease characteristics across cohorts. Hazard ratios (HRs) were computed from a Cox-regression model that included PS-cal"],"journal":["JHLT open"],"pagination":["100462"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12818237"],"repository":["biostudies-literature"],"pubmed_title":["Macitentan and phosphodiesterase-5 inhibitor alone or in combination in newly diagnosed pulmonary arterial hypertension: a pooled analysis."],"pmcid":["PMC12818237"],"pubmed_authors":["Gaine S","Bayer B","Panjabi S","Soderberg S","Linder J","McLaughlin VV","Hennessy B","Paoli CJ","Lange TJ","Sauvageot N","Kim NH"],"additional_accession":[]},"is_claimable":false,"name":"Macitentan and phosphodiesterase-5 inhibitor alone or in combination in newly diagnosed pulmonary arterial hypertension: a pooled analysis.","description":"<h4>Introduction</h4>Upfront combination therapy with endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE5i) is guideline-recommended for low- or intermediate-risk pulmonary arterial hypertension (PAH). This study compared time to all-cause mortality for macitentan+PDE5i combination and each monotherapy.<h4>Methods</h4>Long-term patient-level data (planned follow-up ≥1 year) were pooled from four clinical trials and three observational registries. All-cause mortality data were available from adults with incident PAH initiated on macitentan 10 mg or PDE5i monotherapy, or macitentan+PDE5i. Propensity-score (PS) methods balanced key demographic and disease characteristics across cohorts. Hazard ratios (HRs) were computed from a Cox-regression model that included PS-cal","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-15T06:35:22.177Z","creation":"2026-06-30T03:22:15.502Z"},"accession":"S-EPMC12818237","cross_references":{"pubmed":["41568020"],"doi":["10.1016/j.jhlto.2025.100462"]}}